Ipca Laboratories shares declined by 2.11% to ₹1,421.40 on Tuesday, making it one of the top losers on the Nifty Midcap 150 index. According to reports from Moneycontrol, the stock was trading lower at 3:27 pm, reflecting investor concerns despite the company's recent operational developments. The pharmaceutical company remains a constituent of the Nifty Midcap 150 index, maintaining its position in the mid-cap segment.
The company's consolidated quarterly revenue showed significant fluctuations over the past year, as reported by Moneycontrol. Revenue stood at ₹2,354.90 crore in September 2024, decreased to ₹2,245.37 crore in December 2024, and then increased to ₹2,246.69 crore in March 2025. The revenue trajectory continued with growth to ₹2,308.85 crore in June 2025 and reached ₹2,556.50 crore in September 2025. Net profit followed a similar pattern, with ₹245.44 crore in September 2024, dropping significantly to ₹65.78 crore in March 2025, before recovering to ₹234.42 crore in June 2025 and ₹283.50 crore in September 2025.
According to Moneycontrol reports, consolidated yearly revenue increased consistently from ₹5,419.99 crore in 2021 to ₹8,939.59 crore in 2025. Net profit fluctuated during this period, with ₹1,148.84 crore in 2021, decreasing to ₹910.95 crore in 2022, ₹491.93 crore in 2023, and then increasing to ₹529.21 crore in 2024 and ₹787.53 crore in 2025. Earnings per share varied from ₹45.01 in 2021 to ₹35.14 in 2025, while the debt to equity ratio remained relatively stable, ranging from 0.05 in 2021 to 0.19 in 2025.
As reported by Moneycontrol, Ipca Laboratories announced the commencement of commercial production at its new manufacturing unit in Hingani, Wardha. The company held a concall to discuss Q3FY26 results and scheduled a Board of Directors meeting on February 13, 2026 to approve unaudited financial results for the third quarter and nine months ended December 31, 2025. The company has issued bonus shares with a ratio of 1:1 and underwent a stock split on January 10, 2022, where the old face value of ₹2 was split into a new face value of ₹1.
According to Moneycontrol reports, Ipca Laboratories announced final dividend of ₹2.00 per share on May 29, 2025, with an effective date of August 5, 2025, and interim dividend of ₹2.00 per share on October 24, 2024, with an effective date of November 25, 2024. The company's key financial ratios show basic EPS of ₹35.14 and diluted EPS of ₹29.08 as of March 2025, with book value per share at ₹273.88 and debt to equity ratio of 0.19. The total liabilities increased from ₹6,068 crore in March 2021 to ₹11,760 crore in March 2025, while total assets also grew from ₹6,068 crore to ₹11,760 crore during the same period.
